Skip to main content
Premium Trial:

Request an Annual Quote

AnPac Bio Inks Deal for $3.7M Investment

NEW YORK — AnPac Bio-Medical Science said Monday it has signed an investment agreement that will raise about $3.7 million.

Under the terms of the deal expected to be completed this month, nine institutional investors agreed to buy 36.7 million Class A shares of the Shanghai-based cancer diagnostics firm at $0.10 per share. AnPac co-CEO Chris Yu said in an announcement that the investment would aid operations and research and development, including an ongoing Class III medical device trial needed to commercialize its cancer detection technology.

Earlier this month, AnPac Bio received notice from Nasdaq that it plans to delist the company's stock for failure to regain compliance with a listing requirement of a minimum $1 bid price on the company's stock. The company filed an appeal, and the exchange has granted a hearing scheduled for Oct. 20.

AnPac Bio remains listed on the Nasdaq pending a decision from the hearings panel.

The firm has been under threat of delisting this year for failing to meet other listing requirements related to the minimum market value of publicly held shares and the minimum market value of listed securities.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.